Russell D H, Mills K T, Talamantes F J, Bern H A
Department of Pharmacology and Therapeutics, University of South Florida, College of Medicine, Tampa 33612.
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7404-7. doi: 10.1073/pnas.85.19.7404.
We have evaluated the effect of neonatal administration of mouse prolactin (PRL) antiserum on the developmental expression of T- and B-lymphocytes in the thymus and spleen of female BALB/c mice. Newborn female mice were injected subcutaneously with a 50-microliters aliquot of PRL antiserum or normal rabbit serum on days 1, 2, and 3. On neonatal day 5, the PRL antiserum-treated group had a significantly (P less than 0.05) increased population of cells in the thymus and the spleen that were positive for Thy-1.2 and for L3T4. Increases in Thy-1.2- and L3T4-positive cells in the thymus were detectable also on days 8 and 14 in mice that received the PRL antiserum and in mice injected with bromocriptine, a dopamine agonist that inhibits PRL release from the anterior pituitary. On neonatal days 21, 28, and 32, there were no significant differences in the percentage of cells positive for Thy-1.2, Ly-2 (formerly Lyt-2), or L3T4 antigens in the thymus. However, there were significant increases in the percentage of Thy-1.2- and L3T4-positive spleen cells in the bromocriptine-treated group at all times monitored and in the PRL antiserum-treated group except on day 14. In addition, the percentage of splenocytes that were positive for IgG was significantly increased in the PRL antiserum-treatment group on days 8-28, although not on neonatal day 32. Of tissues known to contain PRL receptors, neonatal administration of PRL antiserum or bromocriptine resulted in a significant alteration in the wet weight of spleen and liver, with no significant effect in thymus, heart, and kidney. Pituitary implants also resulted in a significant increase in both concanavalin A- and lipopolysaccharide-stimulated thymidine incorporation into murine splenic lymphocytes prepared from 45-day-old female mice. These data extend the role of PRL as an immunomodulator of adult lymphocyte function to a role in the developmental expression of T- and B-lymphocyte populations in the thymus and spleen of mice.
我们评估了新生雌性BALB/c小鼠胸腺和脾脏中T淋巴细胞及B淋巴细胞发育表达过程中,给予小鼠催乳素(PRL)抗血清的影响。新生雌性小鼠在出生第1、2和3天皮下注射50微升PRL抗血清或正常兔血清。在出生后第5天,PRL抗血清处理组胸腺和脾脏中Thy-1.2及L3T4阳性细胞数量显著增加(P<0.05)。在出生后第8天和第14天,接受PRL抗血清的小鼠以及注射溴隐亭(一种抑制垂体前叶释放PRL的多巴胺激动剂)的小鼠,胸腺中Thy-1.2及L3T4阳性细胞也有所增加。在出生后第21、28和32天,胸腺中Thy-1.2、Ly-2(原Lyt-2)或L3T4抗原阳性细胞的百分比无显著差异。然而,在所有监测时间点,溴隐亭处理组以及除第14天外的PRL抗血清处理组中,脾脏中Thy-1.2及L3T4阳性细胞的百分比均显著增加。此外,PRL抗血清处理组在出生后第8至28天,脾脏中IgG阳性脾细胞的百分比显著增加,不过在出生后第32天未出现这种情况。在已知含有PRL受体的组织中,给予PRL抗血清或溴隐亭会导致脾脏和肝脏湿重发生显著改变,而对胸腺、心脏和肾脏无显著影响。垂体植入物也导致从45日龄雌性小鼠制备的鼠脾淋巴细胞中,伴刀豆球蛋白A和脂多糖刺激的胸腺嘧啶核苷掺入量显著增加。这些数据将PRL作为成年淋巴细胞功能免疫调节剂的作用扩展至其在小鼠胸腺和脾脏中T淋巴细胞及B淋巴细胞群体发育表达中的作用。